Tradestie Institutional Equity Comparison Engine

TARS vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CVM Overall Edge

CVM Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin while TARS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, TARS trades at 63.7x Forward P/E with -9.6% operating margin (+63.9% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, TARS sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
TARS 63.7x vs CVM 23.0x Fwd P/E
Growth & Margin Winner CVM
Op Margin -9.6% vs 0.0% ยท YoY +63.9% vs -62.7%
Momentum & Technical Winner TARS
1Y +7.3% vs -77.5% ยท 52W Pos 64% vs 10%
Options & Structure Winner TARS
CONSOLIDATION (4th %ile IV) vs BREAKDOWN (N/A IV)
TARS NASDAQ
Tarsus Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.83
-3.06% 1D
Market Cap $3.8B
1M Return +14.33%
1Y Return +7.3%
Forward P/E 63.7x
Unified AI Score
39.5 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 54.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TARS +7.3% CVM -77.48% Spread: +82.71 pp (TARS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period TARS Revenue CVM Revenue TARS Op. Margin CVM Op. Margin Margin Edge
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2021 $60M N/A -21.3% N/A TARS
FY2022 $30M N/A -242.9% N/A TARS
FY2023 $20M N/A -820.5% N/A TARS
FY2024 $180M N/A -65.9% N/A TARS
FY2025 $450M N/A -15.7% N/A TARS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TARS (4) vs CVM (6)
Institutional Metric TARS CVM Criterion Row Winner
Market Capitalization Scale $3.8B $20.9M Larger Scale TARS
Trailing P/E Ratio Valuation 63.7x 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation 63.7x 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth +63.9% -62.7% Higher Growth TARS
Operating Margin (TTM) Profitability -9.6% 0.0% Higher Margin CVM
Net Profit Margin Profitability -102.9% 0.0% Higher Margin CVM
Return on Equity (ROE) Capital Efficiency -319.8% -252.5% Higher ROE CVM
52-Week Range Position Momentum 64% ($54โ€“$92) 10% ($1โ€“$8) Stronger Trend TARS
Beta / 30D Volatility Risk Regime 0.53ฮฒ ยท 45% Vol 0.65ฮฒ ยท 120% Vol Lower Realized Risk TARS
Unified Institutional Score Composite Signal 39.5 / 100 (SELL) 56.6 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TARS vs CVM Buy Guide
TARS CONSOLIDATION
50d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live TARS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TARS nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.